HIV TREATMENT
2020
Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
Paediatric HIV & TB : Rome Action Plan
In pre-clinical and clinical development, initiate paediatric formulation development as soon as a given drug shows potential public health impact in adults, soon after Phase II trials are completed.
Pharmaceutical companies
Sub-Actions & Milestones
Initiate paediatric formulation development as soon as a given drug shows potential public health impact in adults, soon after Phase II trials are completed.
Pharmaceutical companies
ViiV will be increasing resources in Pediatrics further by appointing a Medicine Development Lead to span across the whole R&D portfolio to address these actions.
-
Review ARV portfolio, prioritize PADO products and communicate changes with stakeholders
Pharmaceutical companies
-
-
Demonstrate timely implementation of PADO priorities as part of paediatric portfolio
Pharmaceutical companies
-
-
Updates
Notes
Responsible